CA2263703A1 - A process for producing enteric coated pancreatin granules - Google Patents
A process for producing enteric coated pancreatin granules Download PDFInfo
- Publication number
- CA2263703A1 CA2263703A1 CA002263703A CA2263703A CA2263703A1 CA 2263703 A1 CA2263703 A1 CA 2263703A1 CA 002263703 A CA002263703 A CA 002263703A CA 2263703 A CA2263703 A CA 2263703A CA 2263703 A1 CA2263703 A1 CA 2263703A1
- Authority
- CA
- Canada
- Prior art keywords
- pancreatin
- granules
- process according
- coated
- coating solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010019160 Pancreatin Proteins 0.000 title claims abstract description 64
- 229940055695 pancreatin Drugs 0.000 title claims abstract description 64
- 239000008187 granular material Substances 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 28
- 230000008569 process Effects 0.000 title claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims abstract description 45
- 238000000576 coating method Methods 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 18
- 238000005507 spraying Methods 0.000 claims abstract description 6
- 239000007931 coated granule Substances 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000004014 plasticizer Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- -1 glycerin fatty acid ester Chemical class 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 229960004063 propylene glycol Drugs 0.000 claims description 5
- 235000013772 propylene glycol Nutrition 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000001069 triethyl citrate Substances 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 108010073771 Soybean Proteins Proteins 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 229940023476 agar Drugs 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- BXKIEBLWFRVDHH-UHFFFAOYSA-N butanedioic acid;4-hydroxybutyl acetate Chemical compound OC(=O)CCC(O)=O.CC(=O)OCCCCO BXKIEBLWFRVDHH-UHFFFAOYSA-N 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000019710 soybean protein Nutrition 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 abstract description 6
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 6
- 239000002702 enteric coating Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 238000005056 compaction Methods 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000019626 lipase activity Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A process for producing enteric coated pancreatin granules which comprises spraying the pancreatin powder with a coating solution at a high speed while floating the pancreatin powder at a low temperature to obtain the coated pancreatin granules is disclosed. The granules obtained thus are very stable at acidic pHs and for their tabletting
Description
A PROCESS FOR PRODUCING
ENTERIC COATED PANCREATIN GRANULES
FIEND OF THE INVENTION
The present invention relates to a process for producing enteric-coated pancreatin granules which are stable at acidic pHs and for their tabletting.
BACKGROUND OF THE INVENTION
Pancreatin is a digestive enzyme isolated from the pancreases of mammals, such as cows and pigs, having amylase, protease and lipase activities. It is known that pancreatin can treat cystic fibrosis, pancreatitis, pancreoprivic syndrome and similar conditions. The pancreatic enzymes, produced from the pancreas, are released into the duodenum, the pH of which is close to neutral or slightly alkaline. Under these pH
conditions, the released pancreatic enzymes are active and digestion of the food by the enzymes proceeds normally in the upper segment of the small intestine.
However, when pancreatin is administered exogenously to the patient in need of the treatment for pancreatin malfunction, the gastric conditions in the stomach, namely the presence of acid and pepsin, will irreversibly render the enzymes inactive. Under the acidic conditions the enzymes exhibit 10% to 40% of their normal activity. The acidic pH
especially influences lipase activity. Therefore, orally administered enzymes must be protected against inactivation due to gastric acid so that they remain intact during their transit through the stomach into the duodenum.
The best way to protect the enzymes is through application of an enteric coating.
Two techniques can be used to apply an enteric coating. The first technique, which is well known, involves mixing the pancreatin with an appropriate adjuvant, tabletting the resulting mixture, and applying an enteric coating to the tablets thus obtained. The pancreatin is often used in combination with other digestive enzymes, rather than as a single ingredient. As such, even those among the additional digestive enzymes working in the stomach may be coated and thereby they do not exhibit their benefits sufficiently in the stomach. The other technique is disclosed in U.S. Pat. Nos. 5,260,074 and 5,302,400. It consists of blending pancreatin with the appropriate adjuvant, binder, and organic solvent, granulating the blend, compacting the granulates into spherical particles, drying the spherical particles, and applying an enteric coating to the dried particles.
Specifically, the pancreatin is mixed with the appropriate binder, stabilizer, disintegrant, and organic solvents disclosed in U. S. Pat. No. 4,079,125, followed by granulation of the resulting mixture. The granules thus obtained are molded into beads by Marumerizer compaction and the resulting beads are coated. Alternatively, the pancreatin powder is mixed with a lubricant, and the resulting mixture is compacted into spherical plates using roller compaction, concave compaction or convex compaction. The plates thus obtained are ground, sieved, and coated without organic solvents. This technique is not advantageous as the activity of the enzyme is decreased by the solvent used during granulation and by the heat generated during compaction. The technique is also inefficient because it includes many steps. When the enteric coated granules are tableted, they must be stable against tabletting pressure and must be minute. As such, because the tableting pressure dissipates, the enteric coated granules can be molded without becoming brittle. However, the prior techniques cannot produce minute and uniform granules, and consequently do not result in enteric coated granules stable under acidic conditions and for tabletting.
Therefore, although pancreatin is advantageous when it is used as a complex preparation, i.e., tablet wherein gastric enteric compartments are formed by naked tabletting or gastric coating, there is still a need to develop enteric coated granules stable against tabletting pressure when used singly. We have achieved an improved enteric coating technique ensuring intact activity of the pancreatin in the gastric environment, rapid dissolution of the enteric coated granule in the intestine and stability of the coated granule against tabletting pressure.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides a process for producing enteric coated pancreatin granules which comprises spraying the pancreatin powder with a coating solution at a high speed while floating the pancreatin powder at low temperature to obtain fine coated pancreatin granules, if necessary, again spraying the resulting fine granules with another coating solution, identical to or different from the first coating solution, at a high speed while floating the fine granules at low temperature to produce the coated pancreatin granules.
ENTERIC COATED PANCREATIN GRANULES
FIEND OF THE INVENTION
The present invention relates to a process for producing enteric-coated pancreatin granules which are stable at acidic pHs and for their tabletting.
BACKGROUND OF THE INVENTION
Pancreatin is a digestive enzyme isolated from the pancreases of mammals, such as cows and pigs, having amylase, protease and lipase activities. It is known that pancreatin can treat cystic fibrosis, pancreatitis, pancreoprivic syndrome and similar conditions. The pancreatic enzymes, produced from the pancreas, are released into the duodenum, the pH of which is close to neutral or slightly alkaline. Under these pH
conditions, the released pancreatic enzymes are active and digestion of the food by the enzymes proceeds normally in the upper segment of the small intestine.
However, when pancreatin is administered exogenously to the patient in need of the treatment for pancreatin malfunction, the gastric conditions in the stomach, namely the presence of acid and pepsin, will irreversibly render the enzymes inactive. Under the acidic conditions the enzymes exhibit 10% to 40% of their normal activity. The acidic pH
especially influences lipase activity. Therefore, orally administered enzymes must be protected against inactivation due to gastric acid so that they remain intact during their transit through the stomach into the duodenum.
The best way to protect the enzymes is through application of an enteric coating.
Two techniques can be used to apply an enteric coating. The first technique, which is well known, involves mixing the pancreatin with an appropriate adjuvant, tabletting the resulting mixture, and applying an enteric coating to the tablets thus obtained. The pancreatin is often used in combination with other digestive enzymes, rather than as a single ingredient. As such, even those among the additional digestive enzymes working in the stomach may be coated and thereby they do not exhibit their benefits sufficiently in the stomach. The other technique is disclosed in U.S. Pat. Nos. 5,260,074 and 5,302,400. It consists of blending pancreatin with the appropriate adjuvant, binder, and organic solvent, granulating the blend, compacting the granulates into spherical particles, drying the spherical particles, and applying an enteric coating to the dried particles.
Specifically, the pancreatin is mixed with the appropriate binder, stabilizer, disintegrant, and organic solvents disclosed in U. S. Pat. No. 4,079,125, followed by granulation of the resulting mixture. The granules thus obtained are molded into beads by Marumerizer compaction and the resulting beads are coated. Alternatively, the pancreatin powder is mixed with a lubricant, and the resulting mixture is compacted into spherical plates using roller compaction, concave compaction or convex compaction. The plates thus obtained are ground, sieved, and coated without organic solvents. This technique is not advantageous as the activity of the enzyme is decreased by the solvent used during granulation and by the heat generated during compaction. The technique is also inefficient because it includes many steps. When the enteric coated granules are tableted, they must be stable against tabletting pressure and must be minute. As such, because the tableting pressure dissipates, the enteric coated granules can be molded without becoming brittle. However, the prior techniques cannot produce minute and uniform granules, and consequently do not result in enteric coated granules stable under acidic conditions and for tabletting.
Therefore, although pancreatin is advantageous when it is used as a complex preparation, i.e., tablet wherein gastric enteric compartments are formed by naked tabletting or gastric coating, there is still a need to develop enteric coated granules stable against tabletting pressure when used singly. We have achieved an improved enteric coating technique ensuring intact activity of the pancreatin in the gastric environment, rapid dissolution of the enteric coated granule in the intestine and stability of the coated granule against tabletting pressure.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides a process for producing enteric coated pancreatin granules which comprises spraying the pancreatin powder with a coating solution at a high speed while floating the pancreatin powder at low temperature to obtain fine coated pancreatin granules, if necessary, again spraying the resulting fine granules with another coating solution, identical to or different from the first coating solution, at a high speed while floating the fine granules at low temperature to produce the coated pancreatin granules.
In another aspect, the present invention provides a process for producing pancreatin tablets that comprises spraying the pancreatin powder with a coating solution at a high speed while floating the pancreatin powder at low temperature to obtain fine coated pancreatin granules, if necessary, again spraying the resulting fine granules with another coating solution, identical to or different from the first coating solution, at a high speed to produce the coated pancreatin granules, mixing, based on the total weight of the tablets, from 5% to 80% of the resulting coated granules with a pharmaceutically acceptable adjuvant, and tabletting the resulting mixture.
DETAILED DESCRIPTION OF THE INVENTION
The coating base for this invention includes corn protein extract, sodium alginate, alginic acid, methacrylic acid-ethyl methacrylate copolymer, shellac, carbopol (carbomer~, carboxyvinyl-polymer), hydroxypropylmethylcellulosephthalate, hydroxy-propylmethylcellulose acetate succinate, hydroxypropylmethyl acetate succinate, carboxymethylcellulose, cellulose acetate phthalate, hydroxypropylcellulose, ethyl-cellulose, methylcellulose, polyvinyl acetate phthalate, soybean protein, wheat protein, chitin, chitinic acid, agar, carrageenan, pectin, guar gum, locust bean gum, xanthan gum, gellan gum, arabic gum, and medium chain fatty acid of 6 to 12 carbons. These can be used singly or as a mixture of two or more. The coating base can be used in amounts of from 1 % to 250% based on the total weight of the pancreatin used, preferably from 50%
to 180% by weight.
The plasticizer used for the coating of the present invention includes polyethylene glycol, glycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol, glycerin, triethyl citrate, triacetin, cetyl alcohol, and stearyl alcohol. These can be used as singly or as a mixture of two or more. The plasticizer can be used in amounts of from 1 % to 50% based on the total weight of the pancreatin used, preferably from 5% to 30% by weight.
If the coating base and plasticizer are used in ratios other than those given above, disintegration of the coated granule is delayed or the coating becomes unstable in the gastric fluid. Consequently, the pancreatin either does not act rapidly or its activity decreases.
DETAILED DESCRIPTION OF THE INVENTION
The coating base for this invention includes corn protein extract, sodium alginate, alginic acid, methacrylic acid-ethyl methacrylate copolymer, shellac, carbopol (carbomer~, carboxyvinyl-polymer), hydroxypropylmethylcellulosephthalate, hydroxy-propylmethylcellulose acetate succinate, hydroxypropylmethyl acetate succinate, carboxymethylcellulose, cellulose acetate phthalate, hydroxypropylcellulose, ethyl-cellulose, methylcellulose, polyvinyl acetate phthalate, soybean protein, wheat protein, chitin, chitinic acid, agar, carrageenan, pectin, guar gum, locust bean gum, xanthan gum, gellan gum, arabic gum, and medium chain fatty acid of 6 to 12 carbons. These can be used singly or as a mixture of two or more. The coating base can be used in amounts of from 1 % to 250% based on the total weight of the pancreatin used, preferably from 50%
to 180% by weight.
The plasticizer used for the coating of the present invention includes polyethylene glycol, glycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol, glycerin, triethyl citrate, triacetin, cetyl alcohol, and stearyl alcohol. These can be used as singly or as a mixture of two or more. The plasticizer can be used in amounts of from 1 % to 50% based on the total weight of the pancreatin used, preferably from 5% to 30% by weight.
If the coating base and plasticizer are used in ratios other than those given above, disintegration of the coated granule is delayed or the coating becomes unstable in the gastric fluid. Consequently, the pancreatin either does not act rapidly or its activity decreases.
The solvent for the coating solution of the present invention includes water, alcohol, acetone, acetonitrile,methylene chloride, ether, hexane, chloroform,1,4-dioxane, tetrahydrofuran, dimethyl sulfoxide, ethyl acetate, methyl acetate, or a mixture thereof.
Many fluid beds or similar devices can be used for coating. The fluid bed SFC-MINI (Freund Co., Japan) was used for this invention. The temperature of influx air ranges from 35°C to 70°C. The temperature of the granules must be at least 25°C during the whole procedure in order to prevent aggregation and crumbling of the granules. It is preferable to adjust the temperature of the granules within a range of 25 °C to 60°C during the procedure because the enzyme titer can reduce at temperatures in excess of 60°C.
The following examples illustrate the composition and process forthe preparation of enteric coated pancreatin granules in accordance with the present invention, without limiting the scope thereof.
EXAMPLES
Example 1 The First Coating Seed Pancreatin powder 300 g Coating Solution HPMC 2208 15 g Water I 300 ml Polyethyleneglycol 6000 ~ 2 g The Second Coatine Seed The first fine coated granule 300 g Coating Solution ~ Eudragit~ L 30D ( 1,320 ml (water dispersive) (400 g as solid powder) Water ~ 500 ml I I Propyleneglycol I 40 g (A) Preparation of the first fine coated granules While the pancreatin powder was floated in the fluid bed (SFC-MINI), it was sprayed with the above first coating solution. The product in the fluid bed was adjusted to a temperature of from 25°C to 60°C.
(B) Preparation of the second coated granules While the first fine coated granules were floated in the fluid bed, they were sprayed with the above second coating solution comprising Euragit~ L 30D and a plasticizer. The granules in the fluid bed did not depart from a temperature range of 25 °C
to 60°C. As the second coating base, Kollicoat MAE 30 DP can be used instead.
Example 2 The First Coating Seed Pancreatin powder 300 g Coating Solution Sodium alginate 3 g Water 300 ml Glycerin 3 g The Second Coating Seed The first fine coated granule 300 g Coating Solution Zein-DP~ (corn protein extract) 150 g Shellac 30 g 80% ethanol 1,200 ml Propylene glycol 6 g Glycerin 12 g The first and second coated granules were prepared in the same manner as described in Example 1, but using the above ingredients.
Many fluid beds or similar devices can be used for coating. The fluid bed SFC-MINI (Freund Co., Japan) was used for this invention. The temperature of influx air ranges from 35°C to 70°C. The temperature of the granules must be at least 25°C during the whole procedure in order to prevent aggregation and crumbling of the granules. It is preferable to adjust the temperature of the granules within a range of 25 °C to 60°C during the procedure because the enzyme titer can reduce at temperatures in excess of 60°C.
The following examples illustrate the composition and process forthe preparation of enteric coated pancreatin granules in accordance with the present invention, without limiting the scope thereof.
EXAMPLES
Example 1 The First Coating Seed Pancreatin powder 300 g Coating Solution HPMC 2208 15 g Water I 300 ml Polyethyleneglycol 6000 ~ 2 g The Second Coatine Seed The first fine coated granule 300 g Coating Solution ~ Eudragit~ L 30D ( 1,320 ml (water dispersive) (400 g as solid powder) Water ~ 500 ml I I Propyleneglycol I 40 g (A) Preparation of the first fine coated granules While the pancreatin powder was floated in the fluid bed (SFC-MINI), it was sprayed with the above first coating solution. The product in the fluid bed was adjusted to a temperature of from 25°C to 60°C.
(B) Preparation of the second coated granules While the first fine coated granules were floated in the fluid bed, they were sprayed with the above second coating solution comprising Euragit~ L 30D and a plasticizer. The granules in the fluid bed did not depart from a temperature range of 25 °C
to 60°C. As the second coating base, Kollicoat MAE 30 DP can be used instead.
Example 2 The First Coating Seed Pancreatin powder 300 g Coating Solution Sodium alginate 3 g Water 300 ml Glycerin 3 g The Second Coating Seed The first fine coated granule 300 g Coating Solution Zein-DP~ (corn protein extract) 150 g Shellac 30 g 80% ethanol 1,200 ml Propylene glycol 6 g Glycerin 12 g The first and second coated granules were prepared in the same manner as described in Example 1, but using the above ingredients.
Example 3 The First Coating Seed Pancreatin powder 300 g Coating Solution HPMC 2910 10 g Water 200 ml Glycerin 2 g The Second Coating Seed The first fine coated granule 300 g Coating Solution HPMCP 400 g 80% ethanol 4,000 ml Glycerin fatty acid ester 30 g The first and second coated granules were prepared in the same manner as described in Example 1, but using the above ingredients. HPC can be used instead as the first coating base.
Example 4 The First Coating Seed Pancreatin powder 300 g Coating Solution HPC 10 g Water 200 ml Glycerin 4 g The Second Coating Seed The first fine coated granule 300 g Coating Solution Polyvinylacetatephthalate 450 g Water 4,000 ml Propylene glycol 10 g The first and second coated granules were prepared in the same manner as described in Example 1, but using the above ingredients.
Example 4 The First Coating Seed Pancreatin powder 300 g Coating Solution HPC 10 g Water 200 ml Glycerin 4 g The Second Coating Seed The first fine coated granule 300 g Coating Solution Polyvinylacetatephthalate 450 g Water 4,000 ml Propylene glycol 10 g The first and second coated granules were prepared in the same manner as described in Example 1, but using the above ingredients.
Example 5 Seed Pancreatin powder 300 g Coating Solution HPMCP 400 g 80% ethanol 4,000 ml Glycerine fatty acid ester 30 g The pancreatin was mono-layer coated in the same manner as described in Example 1, but using the above ingredients.
Example 6 Seed Pancreatin powder 300 g Coating Solution Eudragit~ L 30D 1,485 ml (450 g as solid powder) Water 300 ml Triethyl citrate 30 g The pancreatin was mono-layer coated in the same manner as described in Example 1, but using the above ingredients. If desired, Kollicoat 30 DP can be used instead of the above coating base. The preparation of the mono-layer coated granule by increasing the spray rate can prevent reduction of the enzyme titer by the coating solution.
Experimental Example 1 The particle size distribution of the coated granules prepared by Examples 1 through 8 was determined. The results are indicated in Table 1 below.
Table 1. The Particle Size Distribution (%) of the Coated Pancreatin Granule Mesh Size (mm) 20 (0.84) 30 (0.59) 40 (0.42) 50 (0.297) Example 1 7.4 50.5 38.6 3.5 Example 2 9.5 47.6 34.4 8.5 Example 3 9.3 45.8 37.3 7.6 Example 4 11.7 44.1 40.0 4.2 Example 5 4.8 52.2 38.6 4.4 Example 6 9.0 54.7 30.5 5.8 It can be seen from Table 1 that particles of 30 to 40 meshes account for at least 80% of the coated granules. The results indicate that the coated granules prepared by the present invention are uniform.
Experimental Example 2 The coated pancreatin granules prepared by the above Examples 1 to 6 were measured on the activities of lipase, amylase and protease by the pancreatin assay described in the European Pharmacopoeia. The activities were compared to those of the raw pancreatin as control. The results are indicated in Table 2 below.
Table 2 The amount Enzyme activity of (U/mg) pancreatin in the coated Lipase Amylase Protease granule(%) Raw material 73.1 80.5 6.1 Example 38.4 28.3 31.5 2.4 Example 59.1 43.3 47.0 3.6 Example 39.5 28.9 32.0 2.4 Example 37.7 27.4 30.9 2.3 Example 41.1 30.3 33.8 2.6 Example 38.5 28.2 31.3 2.3 _g_ It can be seen from Table 2 that the enzyme titer of the coated pancreatin prepared by the above Examples 1 to 6 is almost consistent with that of the raw pancreatin as control in which the coating base and plasticizer were excluded. The results indicate that the enzyme titer of the pancreatin does not decrease during coating.
Experimental Example 3 From the coated granules prepared by Examples 1 to 6, two were selected depending on mesh size and compressed to obtain tablets. The dissolution test on the obtained tablets was carried out to determine the effect of the tableting pressure on various mesh size coated granules. Microcrystalline cellulose was used as an adjuvant and the amount of the coated granules was 50% by weight of the tablet. Each 800 ml of artificially prepared gastric fluids of pH 2.0 and pH 3.0 was stirred at 100 rpm in Dissolution Test Instrument 1 for 60 minutes. This was transferred to artificially prepared enteric fluid (phosphate buffer, pH 6.0) and was stirred at 100 rpm in Dissolution Test Instrument 2 for 30 minutes. The specimens taken in the proper quantity was tested on lipase activity. The results are indicated in Table below 3.
Table 3 Artificially Artificially produced produced gastric gastric fluid fluid of pH of pH
2.0 3.0 Lipase ToleranceLipase Tolerance activity (%) activity (%) (U/mg) (U/mg) 20-30 mesh23.8 84.1 26.1 92.2 E
l xamp e 30-40 mesh24.7 87.3 27.4 96.8 20-30 mesh15.0 34.6 18.5 42.7 E
l xamp e 30-40 mesh18.0 41.6 19.1 44.1 20-30 mesh24.1 83.4 26.5 91.7 E
l xamp e 30-40 mesh25.0 86.5 27.5 95.2 20-30 mesh23.2 84.7 24.5 89.4 E
l xamp 30-40 mesh24.5 89.4 26.2 95.6 e 20-30 mesh24.9 82.2 27.2 89.8 E
l 5 xamp 30-40 mesh26.5 87.5 28.7 94.7 e 20-30 mesh22.8 80.9 25.1 89.0 E
l xamp 30-40 mesh24.8 87.9 26.8 95.0 e The results of Table 3 indicate that the enteric coated pancreatin granule sufficiently serves as a protective barrier under acidic conditions depending on the mesh size of the granule.
The coating layer of the enteric coated pancreatin granule of the present invention was not broken by the tableting pressure. The acid tolerance test revealed that the larger the coated granule, the more the enzyme titer is reduced. This means that as the smaller coated granule is more able to dissipate or adsorb the tableting pressure, its coating layer is not broken.
Experimental Example 4 The coated pancreatin granules were compressed using the microcrystalline cellulose as an adjuvant. The dissolution test on the resulting tablet was carried out to decide the effect of the adjuvant on the tablet. The coated pancreatin granules of 30 to 40 mesh were used in amounts of 25%, 50%, 75% and 90% by weight based on the tablet.
The absolute amounts of the coated pancreatin granules in the tablets were same. The results are indicated in Table 4 below.
Table 4 Artificiallyproduced Artificiallyproduced gastric d of pH gastric of pH 3.0 flui 2.0 fluid The amount Lipase ToleranceLipase Tolerance of the coatedactivity (%) activity (%) pancreatin (U/mg) (U/mg) granule (%) 25 26.1 92.2 27.9 98.6 50 24.7 87.3 27.4 96.8 l Examp 75 21.2 74.9 24.4 86.2 e 90 18.3 64.7 21.0 74.2 25 20.4 47.1 21.3 49.2 50 18.0 41.6 19.1 44.1 l Examp 75 14.2 32.8 16.7 38.6 e 90 10.5 24.2 13.5 31.2 25 26.8 92.7 28.2 97.6 50 25.0 86.5 27.5 95.2 l Examp 75 22.7 78.5 25.1 86.9 e 90 19.4 67.1 21.0 72.7 25 26.0 94.9 27.0 98.5 50 24.5 89.4 26.2 95.6 l Examp 75 21.7 79.2 23.9 87.2 e 90 19.2 70.1 20.7 75.5 25 28.6 94.4 29.3 96.7 50 26.5 87.5 28.7 94.7 l E
xamp 75 23.2 76.6 26.4 87.1 e 90 20.0 66.0 23.1 76.2 25 26.9 95.4 27.9 98.9 SO 24.8 87.9 26.8 95.0 E
l xamp 75 21.5 76.2 24.0 85.1 e 90 18.7 66.3 21.2 75.2 The results of Table 4 indicate that when the adjuvant in the tablet is used in too small amounts, it cannot serve as a buffer against the tabletting pressure and the coating layer can be easily broken.
Example 6 Seed Pancreatin powder 300 g Coating Solution Eudragit~ L 30D 1,485 ml (450 g as solid powder) Water 300 ml Triethyl citrate 30 g The pancreatin was mono-layer coated in the same manner as described in Example 1, but using the above ingredients. If desired, Kollicoat 30 DP can be used instead of the above coating base. The preparation of the mono-layer coated granule by increasing the spray rate can prevent reduction of the enzyme titer by the coating solution.
Experimental Example 1 The particle size distribution of the coated granules prepared by Examples 1 through 8 was determined. The results are indicated in Table 1 below.
Table 1. The Particle Size Distribution (%) of the Coated Pancreatin Granule Mesh Size (mm) 20 (0.84) 30 (0.59) 40 (0.42) 50 (0.297) Example 1 7.4 50.5 38.6 3.5 Example 2 9.5 47.6 34.4 8.5 Example 3 9.3 45.8 37.3 7.6 Example 4 11.7 44.1 40.0 4.2 Example 5 4.8 52.2 38.6 4.4 Example 6 9.0 54.7 30.5 5.8 It can be seen from Table 1 that particles of 30 to 40 meshes account for at least 80% of the coated granules. The results indicate that the coated granules prepared by the present invention are uniform.
Experimental Example 2 The coated pancreatin granules prepared by the above Examples 1 to 6 were measured on the activities of lipase, amylase and protease by the pancreatin assay described in the European Pharmacopoeia. The activities were compared to those of the raw pancreatin as control. The results are indicated in Table 2 below.
Table 2 The amount Enzyme activity of (U/mg) pancreatin in the coated Lipase Amylase Protease granule(%) Raw material 73.1 80.5 6.1 Example 38.4 28.3 31.5 2.4 Example 59.1 43.3 47.0 3.6 Example 39.5 28.9 32.0 2.4 Example 37.7 27.4 30.9 2.3 Example 41.1 30.3 33.8 2.6 Example 38.5 28.2 31.3 2.3 _g_ It can be seen from Table 2 that the enzyme titer of the coated pancreatin prepared by the above Examples 1 to 6 is almost consistent with that of the raw pancreatin as control in which the coating base and plasticizer were excluded. The results indicate that the enzyme titer of the pancreatin does not decrease during coating.
Experimental Example 3 From the coated granules prepared by Examples 1 to 6, two were selected depending on mesh size and compressed to obtain tablets. The dissolution test on the obtained tablets was carried out to determine the effect of the tableting pressure on various mesh size coated granules. Microcrystalline cellulose was used as an adjuvant and the amount of the coated granules was 50% by weight of the tablet. Each 800 ml of artificially prepared gastric fluids of pH 2.0 and pH 3.0 was stirred at 100 rpm in Dissolution Test Instrument 1 for 60 minutes. This was transferred to artificially prepared enteric fluid (phosphate buffer, pH 6.0) and was stirred at 100 rpm in Dissolution Test Instrument 2 for 30 minutes. The specimens taken in the proper quantity was tested on lipase activity. The results are indicated in Table below 3.
Table 3 Artificially Artificially produced produced gastric gastric fluid fluid of pH of pH
2.0 3.0 Lipase ToleranceLipase Tolerance activity (%) activity (%) (U/mg) (U/mg) 20-30 mesh23.8 84.1 26.1 92.2 E
l xamp e 30-40 mesh24.7 87.3 27.4 96.8 20-30 mesh15.0 34.6 18.5 42.7 E
l xamp e 30-40 mesh18.0 41.6 19.1 44.1 20-30 mesh24.1 83.4 26.5 91.7 E
l xamp e 30-40 mesh25.0 86.5 27.5 95.2 20-30 mesh23.2 84.7 24.5 89.4 E
l xamp 30-40 mesh24.5 89.4 26.2 95.6 e 20-30 mesh24.9 82.2 27.2 89.8 E
l 5 xamp 30-40 mesh26.5 87.5 28.7 94.7 e 20-30 mesh22.8 80.9 25.1 89.0 E
l xamp 30-40 mesh24.8 87.9 26.8 95.0 e The results of Table 3 indicate that the enteric coated pancreatin granule sufficiently serves as a protective barrier under acidic conditions depending on the mesh size of the granule.
The coating layer of the enteric coated pancreatin granule of the present invention was not broken by the tableting pressure. The acid tolerance test revealed that the larger the coated granule, the more the enzyme titer is reduced. This means that as the smaller coated granule is more able to dissipate or adsorb the tableting pressure, its coating layer is not broken.
Experimental Example 4 The coated pancreatin granules were compressed using the microcrystalline cellulose as an adjuvant. The dissolution test on the resulting tablet was carried out to decide the effect of the adjuvant on the tablet. The coated pancreatin granules of 30 to 40 mesh were used in amounts of 25%, 50%, 75% and 90% by weight based on the tablet.
The absolute amounts of the coated pancreatin granules in the tablets were same. The results are indicated in Table 4 below.
Table 4 Artificiallyproduced Artificiallyproduced gastric d of pH gastric of pH 3.0 flui 2.0 fluid The amount Lipase ToleranceLipase Tolerance of the coatedactivity (%) activity (%) pancreatin (U/mg) (U/mg) granule (%) 25 26.1 92.2 27.9 98.6 50 24.7 87.3 27.4 96.8 l Examp 75 21.2 74.9 24.4 86.2 e 90 18.3 64.7 21.0 74.2 25 20.4 47.1 21.3 49.2 50 18.0 41.6 19.1 44.1 l Examp 75 14.2 32.8 16.7 38.6 e 90 10.5 24.2 13.5 31.2 25 26.8 92.7 28.2 97.6 50 25.0 86.5 27.5 95.2 l Examp 75 22.7 78.5 25.1 86.9 e 90 19.4 67.1 21.0 72.7 25 26.0 94.9 27.0 98.5 50 24.5 89.4 26.2 95.6 l Examp 75 21.7 79.2 23.9 87.2 e 90 19.2 70.1 20.7 75.5 25 28.6 94.4 29.3 96.7 50 26.5 87.5 28.7 94.7 l E
xamp 75 23.2 76.6 26.4 87.1 e 90 20.0 66.0 23.1 76.2 25 26.9 95.4 27.9 98.9 SO 24.8 87.9 26.8 95.0 E
l xamp 75 21.5 76.2 24.0 85.1 e 90 18.7 66.3 21.2 75.2 The results of Table 4 indicate that when the adjuvant in the tablet is used in too small amounts, it cannot serve as a buffer against the tabletting pressure and the coating layer can be easily broken.
Claims (11)
1. A process for producing enteric coated pancreatin granules which comprises spraying the pancreatin powder with a coating solution at a high speed while floating the pancreatin powder at a low temperature to obtain the coated pancreatin granules.
2. The process according to claim 1 wherein the resulting coated pancreatin granules are again sprayed with another coating solution, identical to or different from the first coating solution, at a high speed while floating the granules at a low temperature.
3. The process according to claims 1 or 2 wherein the coating base is selected from a group consisting of corn protein extract, sodium alginate, alginic acid, methacrylic acid-ethyl methacrylate copolymer, shellac, carbopol, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethyl acetate succinate, carboxymethylcellulose, cellulose acetate phthalate, hydroxypropylcellulose, ethylcellulose, methylcellulose, polyvinyl acetate phthalate, soybean protein, wheat protein, chitin, chitinic acid, agar, carrageenan, pectin, guar gum, locust bean gum, xanthan gum, gellan gum, arabic gum, and medium chain fatty acid of 6 to 12 carbons.
4. The process according to claims 1 or 2 wherein the plasticizer is selected from a group consisting of polyethylene glycol, glycerin fatty acid ester, sorvitan fatty acid ester, propylene glycol, glycerin, triethyl citrate, triacetin, cetyl alcohol, stearyl alcohol, and mixture thereof.
5. The process according to claims 1 or 2 wherein the plasticizer is used in amounts ranging from 1 % to 50% based on the total weight of the pancreatin used.
6. The process according to claims 1 or 2 wherein the pancreatin is used in amounts ranging from 1% to 95% based on the total weight of the granule.
7. The process according to claims 1 or 2 wherein the coating base is used in amounts ranging from 1% to 250% based on the total weight of the pancreatin used.
8. The process according to claims 1 or 2 wherein the solvent is selected from a group consisting of water, alcohol, acetone, acetonitrile, methylene chloride, ether, hexane, chloroform, 1,4-dioxane, tetrahydrofuran, dimethyl sulfoxide, ethyl acetate, methyl acetate and mixtures thereof.
9. The process according to claims 1 or 2 wherein the whole procedure is conducted at temperatures of 20°C to 70°C.
10. The process according to claims 1 or 2 wherein a fluid bed coater or CF-Granulator are used.
11. A process for producing a pancreatin tablet which comprises mixing, based on the total weight of the tablet, from 5% to 80% of enteric coated granules of claims 1 or 2 with a pharmaceutically acceptable adjuvant and tabletting the resulting mixture.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1998-6064 | 1998-02-26 | ||
KR19980006064 | 1998-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2263703A1 true CA2263703A1 (en) | 1999-08-26 |
Family
ID=19533783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002263703A Abandoned CA2263703A1 (en) | 1998-02-26 | 1999-02-26 | A process for producing enteric coated pancreatin granules |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPH11315032A (en) |
KR (1) | KR19990072826A (en) |
CN (1) | CN1235824A (en) |
CA (1) | CA2263703A1 (en) |
DE (1) | DE19907764A1 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8221747B2 (en) | 2007-02-20 | 2012-07-17 | Aptalis Pharma Limited | Stable pancreatic enzyme compositions |
WO2012169997A1 (en) | 2010-01-15 | 2012-12-13 | Kemin Industries, Inc. | Protected alpha-amylase |
EP2616048A1 (en) * | 2010-11-19 | 2013-07-24 | Curemark, Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
US8778335B2 (en) | 2000-08-14 | 2014-07-15 | Curemark, Llc | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US8802087B2 (en) | 2004-03-22 | 2014-08-12 | Abbott Products Gmbh | Pharmaceutical compositions of lipase-containing products, in particular of pancreation |
US8815233B2 (en) | 1999-12-17 | 2014-08-26 | Curemark Llc | Method for treating pervasive development disorders |
US8921054B2 (en) | 2000-11-16 | 2014-12-30 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
US9017665B2 (en) | 2008-04-18 | 2015-04-28 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US9023344B2 (en) | 2008-03-13 | 2015-05-05 | Curemark, Llc | Method of treating toxemia |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US9259393B2 (en) | 2000-11-15 | 2016-02-16 | Aptalis Pharma S.R.L. | Microspheres of pancreatic enzymes with high stability and production method thereof |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US9345721B2 (en) | 2005-08-30 | 2016-05-24 | Curemark, Llc | Use of lactulose in the treatment of autism |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
EP2818160B1 (en) | 2010-10-01 | 2017-11-08 | Aptalis Pharma Limited | Enteric coated, low-strength pancrelipase formulations |
US9976171B2 (en) | 2011-08-08 | 2018-05-22 | Allergan Pharmaceuticals International Limited | Method for dissolution testing of solid compositions containing digestive enzymes |
NO342633B1 (en) * | 2005-08-15 | 2018-06-25 | Abbott Laboratories Gmbh | Controlled-release pharmaceutical preparations for acid-labile drugs |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
US10184121B2 (en) | 2013-06-28 | 2019-01-22 | Allergan Pharmaceuticals International Limited | Methods for removing viral contaminants from pancreatic extracts |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
US10704037B2 (en) | 2005-07-29 | 2020-07-07 | Abbott Products Gmbh | Processes for the manufacture and use of pancreatin |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US10993996B2 (en) | 2013-08-09 | 2021-05-04 | Allergan Pharmaceuticals International Limited | Digestive enzyme composition suitable for enteral administration |
US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002020061A1 (en) * | 2000-09-07 | 2002-03-14 | Tokyo Gas Company Limited | Preparations for diagnosing extrapancreatic secretory function |
DE10053416A1 (en) | 2000-10-27 | 2002-05-08 | Bsh Bosch Siemens Hausgeraete | Process for the mechanical cleaning of textiles or solid objects |
KR20010007961A (en) * | 2000-10-30 | 2001-02-05 | 류형선 | The preparation method of enteric coated digestive enzyme compositions |
JP4592041B2 (en) * | 2000-11-24 | 2010-12-01 | 株式会社Nrlファーマ | New food production methods and applications that improve quality of life |
JP4494712B2 (en) * | 2002-11-12 | 2010-06-30 | 大日本住友製薬株式会社 | Multiple unit type sustained release formulation |
GB0320020D0 (en) | 2003-08-27 | 2003-10-01 | Mw Encap Ltd | Improved formulation for providing an enteric coating material |
WO2005097082A1 (en) * | 2004-03-31 | 2005-10-20 | Bpsi Holdings, Inc. | Enteric coatings for orally ingestible substrates |
KR101199196B1 (en) * | 2005-07-25 | 2012-11-07 | (주)다산메디켐 | Manufacturing method for spheric granule of pancreatin |
ATE418329T1 (en) * | 2005-08-15 | 2009-01-15 | Solvay Pharm Gmbh | PANCREATIN MICROPELLETS SUITABLE FOR ENTERIC JUICE RESISTANT COATINGS |
CN101242811B (en) * | 2005-08-15 | 2015-06-17 | 雅培实验室有限公司 | Controlled release pharmaceutical compositions for acid labile drugs |
DE102006001554A1 (en) * | 2006-01-05 | 2007-07-12 | Ipc Process-Center Gmbh & Co. | Micropellets for the production of pet food pellets |
EP2295039B2 (en) | 2009-08-28 | 2022-10-26 | Nordmark Pharma GmbH | Pancreatin pellets, in particular pancreatin micropellets and method for producing same |
RU2012142134A (en) * | 2010-03-19 | 2014-04-27 | Апталис Фарма Кэнэда Инк. | GASTRAL RESISTANT ENZYME PHARMACEUTICAL COMPOSITIONS |
CN105007949B (en) * | 2013-03-08 | 2018-07-06 | 狮王株式会社 | Coated composition, coated preparation and its manufacturing method |
JP2016527247A (en) * | 2013-07-22 | 2016-09-08 | アラガン ファーマシューティカルズ インターナショナル リミテッド | High potency pancreatin pharmaceutical composition |
CN106880839B (en) * | 2015-12-14 | 2021-07-13 | 吉林省东鳌鹿业集团有限公司 | Deer bone tablet and preparation method thereof |
DE102017104482A1 (en) * | 2017-03-03 | 2018-09-06 | Nordmark Arzneimittel Gmbh & Co. Kg | A pharmaceutical composition comprising pancreatin and a lipase-containing coating |
KR20210043779A (en) * | 2019-10-11 | 2021-04-22 | 넨시스(주) | Manufacturing method of pancreatin enteric coated pellet |
-
1999
- 1999-02-22 KR KR1019990005822A patent/KR19990072826A/en not_active Application Discontinuation
- 1999-02-23 DE DE19907764A patent/DE19907764A1/en not_active Withdrawn
- 1999-02-25 JP JP11049030A patent/JPH11315032A/en active Pending
- 1999-02-26 CN CN99103124A patent/CN1235824A/en active Pending
- 1999-02-26 CA CA002263703A patent/CA2263703A1/en not_active Abandoned
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9624525B2 (en) | 1999-12-17 | 2017-04-18 | Curemark, Llc | Method for treating pervasive development disorders |
US9624526B2 (en) | 1999-12-17 | 2017-04-18 | Curemark Llc | Method for treating pervasive development disorders |
US8815233B2 (en) | 1999-12-17 | 2014-08-26 | Curemark Llc | Method for treating pervasive development disorders |
US8778335B2 (en) | 2000-08-14 | 2014-07-15 | Curemark, Llc | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US9233146B2 (en) | 2000-08-14 | 2016-01-12 | Curemark, Llc | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
US9884025B2 (en) | 2000-11-15 | 2018-02-06 | Aptalis Pharma S.R.L. | Microspheres of pancreatic enzymes with high stability and production method thereof |
US9259393B2 (en) | 2000-11-15 | 2016-02-16 | Aptalis Pharma S.R.L. | Microspheres of pancreatic enzymes with high stability and production method thereof |
US9377459B2 (en) | 2000-11-16 | 2016-06-28 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US10209253B2 (en) | 2000-11-16 | 2019-02-19 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8921054B2 (en) | 2000-11-16 | 2014-12-30 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8802087B2 (en) | 2004-03-22 | 2014-08-12 | Abbott Products Gmbh | Pharmaceutical compositions of lipase-containing products, in particular of pancreation |
US10704037B2 (en) | 2005-07-29 | 2020-07-07 | Abbott Products Gmbh | Processes for the manufacture and use of pancreatin |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
NO342633B1 (en) * | 2005-08-15 | 2018-06-25 | Abbott Laboratories Gmbh | Controlled-release pharmaceutical preparations for acid-labile drugs |
US9345721B2 (en) | 2005-08-30 | 2016-05-24 | Curemark, Llc | Use of lactulose in the treatment of autism |
US11033563B2 (en) | 2005-08-30 | 2021-06-15 | Curemark, Llc | Use of lactulose in the treatment of autism |
US10350229B2 (en) | 2005-08-30 | 2019-07-16 | Curemark, Llc | Use of lactulose in the treatment of autism |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
EP2079445B1 (en) * | 2007-02-20 | 2015-11-04 | Aptalis Pharma Limited | Stable digestive enzyme compositions |
US8293229B2 (en) | 2007-02-20 | 2012-10-23 | Aptalis Pharma Limited | Methods of producing stable pancreatic enzyme compositions |
US8246950B2 (en) | 2007-02-20 | 2012-08-21 | Aptalis Pharma Limited | Stable digestive enzyme compositions |
US8221747B2 (en) | 2007-02-20 | 2012-07-17 | Aptalis Pharma Limited | Stable pancreatic enzyme compositions |
US10206882B2 (en) | 2007-02-20 | 2019-02-19 | Allergan Pharmaceuticals International Limited | Stable digestive enzyme compositions |
US8562979B2 (en) | 2007-02-20 | 2013-10-22 | Aptalis Pharma Limited | Stable digestive enzyme compositions |
US8562980B2 (en) | 2007-02-20 | 2013-10-22 | Aptalis Pharma Limited | Stable digestive enzyme compositions |
US8562981B2 (en) | 2007-02-20 | 2013-10-22 | Aptalis Pharma Limited | Stable digestive enzyme compositions |
US8562978B2 (en) | 2007-02-20 | 2013-10-22 | Aptalis Pharma Limited | Stable digestive enzyme compositions |
US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
US11045527B2 (en) | 2008-03-13 | 2021-06-29 | Curemark, Llc | Method of diagnosing preeclampsia or pregnancy-induced hypertension |
US9408895B2 (en) | 2008-03-13 | 2016-08-09 | Curemark, Llc | Method of treating pregnancy-induced hypertension |
US9925250B2 (en) | 2008-03-13 | 2018-03-27 | Curemark, Llc | Method of treating proteinuria in pregnancy |
US9023344B2 (en) | 2008-03-13 | 2015-05-05 | Curemark, Llc | Method of treating toxemia |
US9687534B2 (en) | 2008-04-18 | 2017-06-27 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US11235038B2 (en) | 2008-04-18 | 2022-02-01 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US10272141B2 (en) | 2008-04-18 | 2019-04-30 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US9017665B2 (en) | 2008-04-18 | 2015-04-28 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
US10588948B2 (en) | 2008-06-26 | 2020-03-17 | Curemark, Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9687535B2 (en) | 2008-10-03 | 2017-06-27 | Curemark, Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US10413601B2 (en) | 2008-10-03 | 2019-09-17 | Curemark, Llc | Methods and compositions for the treatment of symptoms of prion diseases |
US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9895427B2 (en) | 2009-01-06 | 2018-02-20 | Galenagen, Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US10736946B2 (en) | 2009-01-06 | 2020-08-11 | Galenagen, Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
US11357835B2 (en) | 2009-01-06 | 2022-06-14 | Galenagen, Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
US9931302B2 (en) | 2009-04-13 | 2018-04-03 | Curemark , LLC | Enzyme delivery systems and methods of preparation and use |
US10098844B2 (en) | 2009-04-13 | 2018-10-16 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US11419821B2 (en) | 2009-04-13 | 2022-08-23 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US9415014B2 (en) | 2009-04-13 | 2016-08-16 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
US10716835B2 (en) | 2009-10-21 | 2020-07-21 | Curemark, Llc | Methods and compositions for the prevention and treatment of influenza |
WO2012169997A1 (en) | 2010-01-15 | 2012-12-13 | Kemin Industries, Inc. | Protected alpha-amylase |
EP2557938A1 (en) * | 2010-01-15 | 2013-02-20 | Kemin Industries, Inc. | Protected alpha-amylase |
EP2557938A4 (en) * | 2010-01-15 | 2013-11-20 | Kemin Ind Inc | Protected alpha-amylase |
US11364205B2 (en) | 2010-10-01 | 2022-06-21 | Societe Des Produits Nestle S.A. | Stable low digestive enzyme content formulation |
EP2818160B1 (en) | 2010-10-01 | 2017-11-08 | Aptalis Pharma Limited | Enteric coated, low-strength pancrelipase formulations |
EP2616048A4 (en) * | 2010-11-19 | 2014-04-02 | Curemark Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
EP2616048A1 (en) * | 2010-11-19 | 2013-07-24 | Curemark, Llc | Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
US10940187B2 (en) | 2011-04-21 | 2021-03-09 | Curemark, Llc | Method of treatment of schizophreniform disorder |
US10279016B2 (en) | 2011-04-21 | 2019-05-07 | Curemark, Llc | Method of treatment of schizophreniform disorder |
US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
US9492515B2 (en) | 2011-04-21 | 2016-11-15 | Curemark, Llc | Method of treatment of schizophreniform disorder |
US9976171B2 (en) | 2011-08-08 | 2018-05-22 | Allergan Pharmaceuticals International Limited | Method for dissolution testing of solid compositions containing digestive enzymes |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
US11364287B2 (en) | 2012-05-30 | 2022-06-21 | Curemark, Llc | Methods of treating celiac disease |
US10184121B2 (en) | 2013-06-28 | 2019-01-22 | Allergan Pharmaceuticals International Limited | Methods for removing viral contaminants from pancreatic extracts |
US10993996B2 (en) | 2013-08-09 | 2021-05-04 | Allergan Pharmaceuticals International Limited | Digestive enzyme composition suitable for enteral administration |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Also Published As
Publication number | Publication date |
---|---|
CN1235824A (en) | 1999-11-24 |
DE19907764A1 (en) | 1999-11-04 |
JPH11315032A (en) | 1999-11-16 |
KR19990072826A (en) | 1999-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2263703A1 (en) | A process for producing enteric coated pancreatin granules | |
KR102102198B1 (en) | A delayed release drug formulation | |
AU750911B2 (en) | Enteric coated pharmaceutical composition and method of manufacturing | |
JP5685542B2 (en) | Water-insoluble polymer for colon targeting: starch-based film coating | |
JP2013525488A (en) | Micropellet composition comprising pancreatin containing digestive enzyme mixture | |
JP2011513204A5 (en) | ||
AU2006281414A1 (en) | Controlled release pharmaceutical compositions for acid labile drugs | |
CN101420850A (en) | Formulations for a tight junction effector | |
CZ2001215A3 (en) | Enteric coated pharmaceutical tablet and process for preparing thereof | |
HU227490B1 (en) | Sustained release pharmaceutical preparation containing carvedilol | |
US20140127307A1 (en) | Micropellet compositions comprising pancreatin containing digestive enzyme mixture | |
EP2547331A1 (en) | Gastro-resistant enzyme pharmaceutical compositions | |
CA3026840A1 (en) | Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating | |
AU2005261958A1 (en) | Granules for controlled release of Tamsulosin | |
HRP980376A2 (en) | Delayed-release dosage forms of sertraline | |
US20230190888A1 (en) | Stable lipase formulations and methods thereof | |
JPH05339151A (en) | Sustained release oxybutynin hydrochloride preparation | |
KR100762304B1 (en) | spherical digestive enzyme granules and method for preparing the same | |
WO2022078823A1 (en) | Nutraceutical or pharmaceutical composition comprising a modified starch | |
KR20210100663A (en) | Delayed release drug formulation comprising an outer layer having an enzymatically degradable polymer, compositions thereof, and methods of making the same | |
US8252312B1 (en) | Oral solid composition comprising a lipid absorption inhibitor | |
KR20210100664A (en) | Colon Drug Delivery Formulations | |
KR20020069377A (en) | A process for preparing release controlled granules of quinolone drugs having masked taste and smell | |
WO2021250700A1 (en) | Pharmaceutical composition of pancreatin | |
OA21021A (en) | Pharmaceutical composition of pancreatin. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |